Application of compound medicine in preparation of medicine for resisting new coronavirus

Abstract

The invention discloses an application of a compound medicine in preparation of an anti-new coronavirus medicine, relates to the technical field of medicines, and comprises the following applications: an application of hemp seed oil and curcuma zedoary volatile oil in preparation of the anti-new coronavirus medicine; preparing a medicine for preventing, relieving or treating new coronavirus infection; preparing a medicine for inhibiting proinflammatory cytokines caused by the new coronavirus; the invention relates to inhibition of novel coronavirus for non-therapeutic and diagnostic purposes. The traditional Chinese medicine composition has a prominent anti-inflammatory effect on inflammation caused by new coronavirus infection, can effectively improve the level of inflammatory factors within 3 days, directly relieves the inflammation caused by new coronavirus infection, and is stable in medicine effect. The traditional Chinese medicine composition has the effects of resisting oxidation, improving digestion, resisting viruses and the like, comprehensively improves symptoms and does not have obvious toxic or side effects.

Description

TECHNICAL FIELD

[0001] The application relates to the technical field of medicines, in particular to application of a compound medicine in preparation of an anti-coronavirus medicine. BACKGROUND

[0002] After coronavirus infection, some patients may develop severe pneumonia or acute respiratory distress syndrome (ARDS), and the core pathological mechanism includes immune response to the virus, excessive inflammatory response (cytokine storm) and immunosuppression, which requires drug intervention to achieve inflammation regulation while resisting the virus.

[0003] At present, the strategies are mainly anti-viral drugs combined with immunomodulators, glucocorticoids, traditional Chinese medicine anti-inflammatory compounds, etc., such as remdesivir + tocilizumab, dexamethasone + remdesivir, and Lianhuaqingwen + low molecular weight heparin. The anti-inflammatory drugs used in the above-mentioned schemes, including baricitinib and tocilizumab, are inflammatory effector signal inhibitors or receptor antagonists, which have the limitations of single function, increased risk of bacterial / fungal infection, side effects on internal organs, etc.; the traditional Chinese medicine compound Lianhuaqingwen relies on the components contained in Rhodiola and Dahuang to reduce inflammatory factors such as IL-6 and TNF-alpha, and faces the problems of unstable or insignificant efficacy, mainly symptom relief, and insufficient international recognition. SUMMARY

[0004] The application aims to provide application of a compound medicine in preparation of an anti-coronavirus medicine, so as to solve the problems of single function of western medicine, increased risk of bacterial / fungal infection, side effects on internal organs, and unstable or insignificant efficacy of traditional Chinese medicine.

[0005] To achieve the above-mentioned purpose, the application provides the following technical scheme:

[0006] Application of a compound medicine in preparation of an anti-coronavirus medicine, including application of cannabis seed oil and zedoary volatile oil in (1)-(4) as follows:

[0007] (1) application in preparation of an anti-coronavirus medicine;

[0008] (2) preparation of a medicine for preventing, relieving or treating coronavirus infection;

[0009] (3) preparation of a medicine for inhibiting pro-inflammatory cytokines caused by coronavirus;

[0010] (4) inhibition of coronavirus for non-treatment and diagnosis purposes;

[0011] The pro-inflammatory cytokines include IFN-gamma, IL-1beta, IL-6 and TNF-alpha.

[0012] Further, the cannabis seed oil and zedoary volatile oil are prepared into oral liquid for use.

[0013] The principle and beneficial effects of the technical solution are as follows:

[0014] 1、 The application has outstanding anti-inflammatory effect on inflammation caused by new coronavirus infection, can effectively improve the level of inflammatory factors within 3 days, directly relieves inflammation caused by new coronavirus infection, and the drug effect is stable.

[0015] 2、 The application has the effects of antioxidant, improving digestion, and antiviral, and can comprehensively improve the inflammatory symptoms.

[0016] 3、 The application has no obvious toxic and side effects. DETAILED DESCRIPTION

[0017] Figure 1 It is a schematic diagram of body weight change of mice within 3 days after LPS induction;

[0018] Figure 2 It is a schematic diagram of lung pathological HE staining of mice at 24 and 72 hours of infection;

[0019] Figure 3 It is a comparison of the levels of pro-inflammatory cytokines in the serum of mice in each group at 72 hours of infection;

[0020] Figure 4 It is a comparison of the levels of pro-inflammatory cytokines in the bronchoalveolar lavage fluid of mice in each group at 72 hours of infection. DETAILED DESCRIPTION

[0021] In order to make the purpose, technical solution and advantages of the application more clear and obvious, the application will be further described in detail below in combination with embodiments and drawings. Herein, the illustrative embodiments of the application and their descriptions are used to explain the application, but not as a limitation of the application.

[0022] It should be noted that, in order to avoid obscuring the application due to unnecessary details, only the processing steps closely related to the solution of the application are shown, and other details not closely related to the application are omitted.

[0023] It should be emphasized that the term "comprising / including" is used herein to indicate the presence of a feature or element, but does not exclude the presence or addition of one or more other features or elements.

[0024] The compound of the application is an oral liquid developed based on hemp seed oil and zedoary volatile oil, which is referred to as hemp-zedoary oral liquid (HEKFY).

[0025] The human ACE2 (hACE2) gene is introduced into the mouse body using an adenovirus vector, and SARS-CoV-2 infection is applied to construct a new coronavirus infection mouse model.

[0026] At 1h, 12h, 24h, 48h, 72h after infection, the fire calyx oral liquid was administered by gavage, and the single dose was 0.1 ml / 20kg of body weight. Based on the data of the mouse COVID-19 model infected by the new coronavirus, the fire calyx oral liquid can reduce the weight loss of mice to a certain extent, and the reference is Figure 1 The body weight of the control group (Ctrl), the model group (COVID-19) and the fire calyx oral liquid administration group (COVID-19+HEKFY) mice was changed within 3 days after LPS induction.

[0027] At 24h and 72h after viral infection, HE staining was performed on the lungs of each group, and it was found that the lungs of the LPS group had a large area of alveolar filling and inflammatory infiltration. The lung pathological region of the fire calyx oral liquid administration group was greatly improved, the alveolar cavity area was increased, and the inflammatory area was greatly reduced, and the reference is Figure 2 The lung pathological HE staining of the control group (Ctrl), the LPS-induced model group (COVID-19) and the fire calyx oral liquid administration group (COVID-19+HEKFY) mice was performed at 24h and 72h after infection.

[0028] At 72h after viral infection, the serum cytokine detection results of each group of mice showed that the levels of inflammatory signals IFN-γ, IL-1β, IL-6 and TNF-α in the serum of the COVID-19 group of mice were increased to different degrees, and the level of IL-1β was increased most significantly. The fire calyx oral liquid administration significantly reduced the level, and the reference is Figure 3 The levels of pro-inflammatory cytokines in the serum of each group of mice at 72h after infection were compared.

[0029] At 72h after viral infection, the detection results of pro-inflammatory cytokines in the bronchoalveolar lavage fluid (BALF) of each group of mice showed that the levels of inflammatory signals IFN-γ, IL-1β, IL-6 and TNF-α in the BALF of the COVID-19 group of mice were significantly increased, and the fire calyx oral liquid administration significantly reduced the levels of all these cytokines, and the reference is Figure 4 The levels of pro-inflammatory cytokines in the bronchoalveolar lavage fluid (BALF) of each group of mice at 72h after infection were compared.

[0030] In summary, the present application finds that the oral liquid developed based on hemp seed oil and zedoary volatile oil has outstanding anti-inflammatory effect on inflammation caused by COVID-19 infection, can effectively improve the lung inflammatory factor level within 3 days, directly relieve the inflammation caused by COVID-19 infection, has stable efficacy, and at the same time has antioxidant, digestion improvement, antiviral and other effects, and can comprehensively improve the inflammation symptoms. Therefore, the application of a compound medicine in the preparation of an anti-COVID-19 medicine is proposed, including the application of hemp seed oil and zedoary volatile oil in (1)-(4) as follows:

[0031] (1) Application of preparing anti-coronavirus drugs;

[0032] (2) Application of preparing drugs for preventing, alleviating or treating coronavirus infection;

[0033] (3) Application of preparing drugs for inhibiting proinflammatory cytokines caused by coronavirus;

[0034] (4) Inhibition of coronavirus for non-therapeutic and diagnostic purposes;

[0035] Wherein, the proinflammatory cytokines include IFN-gamma, IL-1beta, IL-6 and TNF-alpha.

[0036] It should be noted that the present application is not limited to the specific configurations and processes described above and shown in the drawings. For the sake of brevity, detailed descriptions of well-known methods are omitted here.

[0037] In the present application, the features described and / or exemplified for one embodiment can be used in the same way or in an analogous way in one or more other embodiments, and / or in combination with or instead of features of other embodiments.

[0038] The above only describes the preferred embodiments of the present application, and is not intended to limit the present application. The embodiments of the present application can be variously changed and modified by those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application shall be included in the protection scope of the present application.

Claims

1. The application of a compound drug in the preparation of anti-COVID-19 drugs, characterized in that, The applications of hemp seed oil and turmeric volatile oil are as follows (1)-(4): (1) Application in the preparation of anti-COVID-19 drugs; (2) To prepare drugs for the prevention, relief or treatment of COVID-19 infection; (3) To prepare drugs that inhibit pro-inflammatory cytokines induced by the novel coronavirus; (4) Suppression of the novel coronavirus for non-therapeutic and non-diagnostic purposes; The pro-inflammatory cytokines include IFN-γ, IL-1β, IL-6, and TNF-α.

2. The application of the compound drug according to claim 1 in the preparation of anti-COVID-19 drugs, characterized in that, The hemp seed oil and turmeric volatile oil are prepared as an oral liquid for use.

Images